Close
ACHEMA MIDDLE EAST 2026

Guidance On CAR-T Cell Product Development Issued By FDA

The FDA has gone on to publish its final guidance on January 30, 2024, that goes on to offer consideration for the development of...

EMA Given Aid To Support African Medicines Agency Setup

The European Medicines Agency- EMA went on to announce on January 26, 2024, that the European Commission-EC has gone ahead and given the agency...

Possible Autoimmune Breakthrough With BCMA CAR T Therapy

It is well to be noted that the positive results from the first global study for chimeric antigen receptor (CAR)-antologous T cell- BCMA CAR...

NHSs BRCA Gene Testing Programme To Ascertain Cancer Risk

The BRCA gene testing initiative looks to identify individuals who carry genetic faults associated with an elevated risk of specific cancers, thereby enabling early...

Prescribe Fluoroquinolone Antibiotics As Last Resort – MHRA

It has been determined that fluoroquinolone antibiotics should only be prescribed in cases where no other antibiotics happen to be appropriate for use, as...

Breast Cancer Ranked Highest On Most Studied Diseases List

Oncology research has gone on to attain priority status and has apparently been flush with pharma research dollars for years. The fact is that...

Medicines For Europe Calls Simpler SPC Manufacturing Waiver

As per Medicines for Europe, the Munich District Court’s Supplementary Protection Certificate- SPC manufacturing waiver, which was issued in Germany in October last year,...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...